Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability and accessibility, today ...
Curevo's CEO, George Simeon, will discuss updated data from Curevo's 876-patient head-to-head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix®.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback